Why Amarin Shares Got Crushed

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of biotech Amarin (NASDAQ: AMRN  ) plummeted 20% today after announcing plans to hire a sales force for the launch of its cholesterol-reducing fish-oil pill Vascepa.

So what: The start of an independent sales force, coupled with a $100 million non-equity financing, suggests that Amarin will have to launch Vascepa on its own and that a buyout is no longer on the horizon. Of course, on a conference call CEO Joe Zakrzewski insisted that "all options are still on the table" and that "partner discussions were still active," giving Amarin bulls a glimmer of hope that a deal is still possible.

Now what: Unfortunately, Amarin still isn't sure when the Food and Drug Administration will issue a ruling on Vascepa's New Chemical Entity, or NCE, status, adding even more uncertainty to the situation. Given that the stock will continue to move wildly on news or speculation tied to the NCE status, as well as management's strategic talks, only biotech-savvy bargain hunters should consider jumping in at this point. While Amarin's upside remains juicy, the volatility and downside might be too much for average Fools to handle.

Of course, that doesn't come close to telling the entire story of Amarin. The Fool's brand new premium report on Amarin has all the details -- with an exclusive update on today's news. You can grab your copy, which comes with free updates for 12 months, by just clicking here.


Read/Post Comments (0) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2144458, ~/Articles/ArticleHandler.aspx, 4/19/2014 8:56:13 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement